Neurology Medical News about Glioblastoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Six year survival after prolonged temozolomide treatment in a 30 year old patient with glioblastoma
Acta Neurologica Belgica, 10/21/09

Poelen J et al. – The authors report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.

<< Previous
Lack of association between the Paraoxonase 1 Q/R192 single...

Next >>
Cross-sectional Assessment of the Consequences of a GTP...

Distribution, cellular localization, and therapeutic potential of the tumor-associated antigen Ku70/80 in glioblastoma multiforme
Journal of Neuro-Oncology, 10/28/09 Relevance Score: 88%

Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the Treatment
Clinical Cancer Research, 10/01/09 Relevance Score: 88%

Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature
Journal of Neuro-Oncology, 11/18/09 Relevance Score: 87%

Antiglioma Immunological Memory in Response to Conditional Cytotoxic/Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression
Clinical Cancer Research, 10/06/09 Relevance Score: 87%

Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme
Journal of Neuro-Oncology, 10/01/09 Relevance Score: 87%